Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Kartos Therapeutics Partner to Develop TP53 Companion Diagnostic

NEW YORK – Illumina and Kartos Therapeutics announced a partnership on Thursday to develop a next generation sequencing-based TP53 companion diagnostic.

The diagnostic will be based on Illumina's pan-cancer comprehensive genomic profiling assay, TruSight Oncology 500, or TSO 500, and will be used to detect TP53 mutations in multiple hematologic indications. The partnership will initially focus on developing a companion diagnostic for Kartos's MDM2 inhibitor, KRT-232.

Kartos has several ongoing clinical trials for KRT-232 in TP53 wild-type blood cancers, including acute myeloid leukemia, myelofibrosis, polycythemia vera, chronic myelogenous leukemia, and B-cell malignancies.

"Kartos is dedicated to developing novel, targeted therapeutics that meaningfully improve the lives of patients with cancer," Jesse McGreivy, Kartos' CEO and CMO, said in a statement. "This partnership will allow us to capitalize on TSO 500 as we explore the expanded use of KRT-232, which offers a unique mechanism to restore the function of p53, one of the most critical tumor suppressor proteins, resulting in apoptosis of malignant cells across a variety of hematologic and solid tumor types."

Redwood City, California-based Kartos is also studying KRT-232 in some solid tumors with TP53 mutations, such as glioblastoma, soft tissue sarcoma, and Merkel cell carcinoma.

Illumina's TSO 500 is currently used only for research and can identify 523 known and emerging tumor biomarkers. The new diagnostic will be the first to use TSO 500 with peripheral whole blood as a sample type.

This year, Illumina has also inked companion diagnostic partnerships with Bristol Myers Squibb, Kura Oncology, Merck, Myriad Genetics, and Qiagen.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.